An Overview of Cancer Prevention: Chemoprevention and Immunoprevention

다국어 초록 (Multilingual Abstract)

Cancer prevention encompasses a broad spectrum of strategies designed to lower the chance of developing cancer and reduce the morbidity of established cancer. There are three levels of cancer prevention. Eliminating or mitigating cancer risk factors by adopting healthy behaviors and lifestyles, such as avoiding tobacco and alcohol use, exercising, eating a healthy diet, and applying sunscreen to protect against UV exposure, belongs to primary prevention and is the easiest and most effective way of preventing cancer for the general public. Secondary prevention includes screening to identify precancerous lesions and taking intervention measures to prevent disease progression to malignancy. Tertiary prevention refers to reducing or controlling the symptoms and morbidity of established cancer or the morbidity caused by cancer therapy. For high-risk populations, chemopreventive agents, such as selective estrogen receptor modulators (including tamoxifan and raloxifene) in breast cancer prevention and non-steroidal anti-inflammatory drugs (aspirin) in colorectal cancer prevention, and immunoprevention using human papillomavirus and hepatitis B virus vaccines in infection-related cancers have shown clear clinical benefits of reducing cancer incidences. In this review, we will summarize the current status of cancer prevention, focusing on the major agents that are clinically used for chemoprevention and immunoprevention.

참고문헌 (Reference)

1 Lollini PL, "Vaccines and other immunological approaches for cancer immunoprevention" 12 : 1957-1973, 2011

2 Beatty PL, "Vaccine against MUC1 antigen expressed in inflammatory bowel disease and cancer lessens colonic inflammation and prevents progression to colitis-associated colon cancer" 3 : 438-446, 2010

3 Vogel VG, "Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene(STAR)P-2 Trial : preventing breast cancer" 3 : 696-706, 2010

4 Bibbins-Domingo K, "U.S. Preventive Services Task Force. Aspirin use for the primary prevention of cardiovascular disease and colorectal cancer: U.S. Preventive Services Task Force recommendation statement" 164 : 836-845, 2016

5 Powles TJ, "Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial" 99 : 283-290, 2007

6 Levingston CA, "Transient immunological and clinical effectiveness of treating mice bearing premalignant oral lesions with PD-1 antibodies" 140 : 1609-1619, 2017

7 Cheever MA, "The prioritization of cancer antigens : a national cancer institute pilot project for the acceleration of translational research" 15 : 5323-5337, 2009

8 Subbiah V, "The marriage between genomics and immunotherapy : mismatch meets its match" 24 : 1-3, 2019

9 Mantovani F, "The human papillomavirus E6 protein and its contribution to malignant progression" 20 : 7874-7887, 2001

10 Zanetti AR, "The global impact of vaccination against hepatitis B : a historical overview" 26 : 6266-6273, 2008

11 Thun MJ, "The global burden of cancer : priorities for prevention" 31 : 100-110, 2010

12 Moasser MM, "The evolving landscape of HER2targeting in breast cancer" 1 : 1154-1161, 2015

13 Veronesi U, "Tamoxifen for the prevention of breast cancer : late results of the Italian Randomized Tamoxifen Prevention Trial among women with hysterectomy" 99 : 727-737, 2007

14 Fisher B, "Tamoxifen for the prevention of breast cancer : current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study" 97 : 1652-1662, 2005

15 Fisher B, "Tamoxifen for prevention of breast cancer : report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study" 90 : 1371-1388, 1998

16 Harper DM, "Sustained efficacy up to 4. 5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18 : follow-up from a randomised control trial" 367 : 1247-1255, 2006

17 Lytras T, "Statins and the risk of colorectal cancer : an updated systematic review and metaanalysis of 40 studies" 20 : 1858-1870, 2014

18 Boudreau DM, "Statin use and cancer risk : a comprehensive review" 9 : 603-621, 2010

19 Thorat MA, "Role of aspirin in cancer prevention" 15 : 533-540, 2013

20 Vaddepally RK, "Review of indications of FDA-approved immune checkpoint inhibitors per NCCN guidelines with the level of evidence" 12 : 738-, 2020

21 Fracol M, "Response to HER-2 pulsed DC1 vaccines is predicted by both HER-2 and estrogen receptor expression in DCIS" 20 : 3233-3239, 2013

22 Gazzerro P, "Pharmacological actions of statins : a critical appraisal in the management of cancer" 64 : 102-146, 2012

23 Wang J, "PD-1 blockade prevents the development and progression of carcinogen-induced oral premalignant lesions" 10 : 684-693, 2017

24 Maresso KC, "Molecular cancer prevention : current status and future directions" 65 : 345-383, 2015

25 Romero R, "Metformin, the aspirin of the 21st century : its role in gestational diabetes mellitus, prevention of preeclampsia and cancer, and the promotion of longevity" 217 : 282-302, 2017

26 Morales DR, "Metformin in cancer treatment and prevention" 66 : 17-29, 2015

27 Decensi A, "Metformin and cancer risk in diabetic patients : a systematic review and meta-analysis" 3 : 1451-1461, 2010

28 Nelson HD, "Medication use for the risk reduction of primary breast cancer in women : updated evidence report and systematic review for the US Preventive Services Task Force" 322 : 868-886, 2019

29 Vlad AM, "MUC1immunobiology : from discovery to clinical applications" 82 : 249-293, 2004

30 Kimura T, "MUC1 vaccine for individuals with advanced adenoma of the colon : a cancer immunoprevention feasibility study" 6 : 18-26, 2013

31 Webster GJ, "Longitudinal analysis of CD8+ T cells specific for structural and nonstructural hepatitis B virus proteins in patients with chronic hepatitis B : implications for immunotherapy" 78 : 5707-5719, 2004

32 Cuzick J, "Long-term results of tamoxifen prophylaxis for breast cancer--96-month follow-up of the randomized IBIS-I trial" 99 : 272-282, 2007

33 Rothwell PM, "Long-term effect of aspirin on colorectal cancer incidence and mortality : 20-year follow-up of five randomised trials" 376 : 1741-1750, 2010

34 Levingston CA, "Local immune responsiveness of mice bearing premalignant oral lesions to PD-1 antibody treatment" 9 : 62-, 2017

35 Rao CV, "Immunoprevention of pancreatic cancer" 25 : 2576-2584, 2018

36 Wojtowicz ME, "Immunologic approaches to cancer prevention-current status, challenges, and future perspectives" 43 : 161-172, 2016

37 Willis JA, "Immune activation in mismatch repair-deficient carcinogenesis : more than just mutational rate" 26 : 11-17, 2020

38 Lee LY, "Human papillomavirus vaccination : the population impact" 6 : 866-, 2017

39 Ni YH, "Hepatitis B vaccination in children : the Taiwan experience" 58 : 296-300, 2010

40 Romanò L, "Hepatitis B vaccination" 11 : 53-57, 2015

41 Sharma A, "HER-2 pulsed dendritic cell vaccine can eliminate HER-2 expression and impact ductal carcinoma in situ" 118 : 4354-4362, 2012

42 Conway JR, "Genomics of response to immune checkpoint therapies for cancer : implications for precision medicine" 10 : 93-, 2018

43 Krstic MN, "General aspects of primary cancer prevention" 37 : 406-415, 2019

44 Goss PE, "Exemestane for breastcancer prevention in postmenopausal women" 364 : 2381-2391, 2011

45 Ebben JD, "Epidermal growth factor receptor derived peptide vaccination to prevent lung adenocarcinoma formation : an in vivo study in a murine model of EGFR mutant lung cancer" 55 : 1517-1525, 2016

46 Harper DM, "Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women : a randomised controlled trial" 364 : 1757-1765, 2004

47 Vogel VG, "Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes : the NSABP Study of Tamoxifen and Raloxifene(STAR)P-2 trial" 295 : 2727-2741, 2006

48 Rothwell PM, "Effect of daily aspirin on long-term risk of death due to cancer : analysis of individual patient data from randomised trials" 377 : 31-41, 2011

49 Boyer SN, "E7 protein of human papilloma virus-16 induces degradation of retinoblastoma protein through the ubiquitin-proteasome pathway" 56 : 4620-4624, 1996

50 서성환, "Diabetes and Cancer: Cancer Should Be Screened in Routine Diabetes Assessment" 대한당뇨병학회 43 (43): 733-743, 2019

51 Benamouzig R, "Cyclooxygenase-2 expression and recurrence of colorectal adenomas : effect of aspirin chemoprevention" 59 : 622-629, 2010

52 Bosch FX, "Comprehensive control of human papillomavirus infections and related diseases" 31 (31): H1-H31, 2013

53 Pruthi S, "Chemoprevention for breast cancer" 22 : 3230-3235, 2015

54 Siegel RL, "Cancer statistics, 2020" 70 : 7-30, 2020

55 Meyskens FL Jr, "Cancer prevention: obstacles, challenges and the road ahead" 108 : djv309-, 2015

56 Chang MH, "Cancer prevention by vaccination against hepatitis B" 181 : 85-94, 2009

57 Mancuso JG, "Cancer immunoprevention:a case report raising the possibility of “immuno-interception”" 13 : 351-356, 2020

58 Palladini A, "Cancer immunoprevention : from mice to early clinical trials" 19 : 16-, 2018

59 Finn OJ, "Cancer immunoprevention" 39 : 52-58, 2016

60 Andrews MC, "Cancer evolution during immunotherapy" 171 : 740-742, 2017

61 World Health Organization, "Cancer"

62 Buchbinder EI, "CTLA-4 and PD-1 pathways : similarities, differences, and implications of their inhibition" 39 : 98-106, 2016

63 Chan AT, "COX-2 expression in adenoma : an imperfect marker for chemoprevention" 59 : 568-569, 2010

64 Krummel MF, "CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation" 182 : 459-465, 1995

65 Chen Y, "Blockade of PD-1 effectively inhibits in vivo malignant transformation of oral mucosa" 7 : e1388484-, 2017

66 Gronich N, "Beyond aspirin-cancer prevention with statins, metformin and bisphosphonates" 10 : 625-642, 2013

67 Lohmueller JJ, "Antibodies elicited by the first non-viral prophylactic cancer vaccine show tumor-specificity and immunotherapeutic potential" 6 : 31740-, 2016

68 Cuzick J, "Anastrozole for prevention of breast cancer in high-risk postmenopausal women(IBIS-II) : an international, double-blind, randomised placebo-controlled trial" 383 : 1041-1048, 2014